Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Novo Nordisk A/S
NVO
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $216.7B
$50.35
▲ +3.24%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$35.12 - $71.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 30.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Market leadership in insulin and diabetes care with 100+ years of expertise
- Proprietary GLP-1 portfolio addressing obesity and cardiometabolic diseases
- Integrated delivery systems and digital health solutions enhancing patient outcomes
- Strong R&D pipeline and strategic partnerships accelerating innovation
- Global manufacturing and distribution network across 170+ countries
Bear Case
2 risks
- Low volatility (beta 0.3).
- Growth premium of 0.2x vs Large Cap Pharma peers. Reasonable for this growth rate.
Growth
Strong growth ahead
Rising global obesity and type 2 diabetes prevalence driving demand
Value
Growth premium of 0.2x vs Large Cap Pharma peers. Reasonable for this growth rate.
Momentum
Hot
+31.9% over 3m
Quality
Excellent
High-growth business (190% revenue growth, 82% gross margin). Profitable with strong growth momentum.
Dividend
Solid
3.61% yield
Smart-money signal
Who's buying NVO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 6, 2026
Reported EPS of $1.04 vs $0.87 consensus (+19.5% surprise). Revenue of $11.0B vs $10.9B expected (+1.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+19.5%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
+30%
+19%
+13%
+5%
+494%
+24%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.6B
$1.7B
$2.1B
$12.1B
$11.9B
$11.6B
$12.3B
$15.0B
Margins · last 8Q
Gross
86.0%
Operating
61.6%
Profit
50.1%
Wall Street consensus
3 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
—
Latest: Nordea · Jun 19, 2026